Bank of America
CBIO

Bank of America’s Crescent Biopharma CBIO Stock Holding History

Bank of America’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538K Buy
29,277
+23,704
+425% +$272K ﹤0.01% 4858
2025
Q4 		$66.1K Buy
5,573
+1,710
+44% +$21.8K ﹤0.01% 5755
2025
Q3 		$45.9K Sell
3,863
-5,368
-58% -$71.2K ﹤0.01% 6864
2025
Q2 		$149K Buy
9,231
+9,223
+115,288% +$195K ﹤0.01% 6321
2025
Q1 		$165 Hold
8
– – ﹤0.01% 7733
2024
Q4 		$190 Buy
8
+3
+60% +$82 ﹤0.01% 7597
2024
Q3 		$78 Sell
5
-49
-91% -$1.03K ﹤0.01% 7759
2024
Q2 		$1.52K Sell
54
-455
-89% -$47.3K ﹤0.01% 7176
2024
Q1 		$153K Buy
509
+309
+155% +$92.3K ﹤0.01% 6023
2023
Q4 		$47.2K Buy
200
+118
+144% +$18.3K ﹤0.01% 6614
2023
Q3 		$12.3K Buy
82
+1
+1% +$158 ﹤0.01% 6812
2023
Q2 		$14.1K Sell
81
-1
-1% -$168 ﹤0.01% 6785
2023
Q1 		$10.4K Buy
82
+81
+8,100% +$18.2K ﹤0.01% 6909
2022
Q4 		$358 Sell
1
-92
-99% -$13.6K ﹤0.01% 7474
2022
Q3 		$6K Hold
93
– – ﹤0.01% 7346
2022
Q2 		$6K Sell
93
-65
-41% -$4.81K ﹤0.01% 7546
2022
Q1 		$18K Buy
158
+41
+35% +$4.81K ﹤0.01% 7557
2021
Q4 		$17K Sell
117
-31
-21% -$5.63K ﹤0.01% 7564
2021
Q3 		$32K Sell
148
-246
-62% -$52.1K ﹤0.01% 7236
2021
Q2 		$91K Sell
394
-106
-21% -$27K ﹤0.01% 6559
2021
Q1 		$151K Buy
500
+314
+169% +$112K ﹤0.01% 6213
2020
Q4 		$70K Sell
186
-1,809
-91% -$634K ﹤0.01% 6161
2020
Q3 		$612K Buy
1,995
+1,856
+1,335% +$709K ﹤0.01% 4567
2020
Q2 		$52K Buy
139
+49
+54% +$13.9K ﹤0.01% 5966
2020
Q1 		$20K Sell
90
-2
-2% -$764 ﹤0.01% 6172
2019
Q4 		$49K Sell
92
-143
-61% -$77.4K ﹤0.01% 6267
2019
Q3 		$102K Sell
235
-166
-41% -$107K ﹤0.01% 6039
2019
Q2 		$477K Buy
401
+119
+42% +$142K ﹤0.01% 5097
2019
Q1 		$352K Buy
282
+218
+341% +$250K ﹤0.01% 5227
2018
Q4 		$61K Sell
64
-91
-59% -$110K ﹤0.01% 6137
2018
Q3 		$223K Sell
155
-236
-60% -$357K ﹤0.01% 5436
2018
Q2 		$631K Buy
391
+246
+170% +$423K ﹤0.01% 4764
2018
Q1 		$235K Buy
145
+75
+107% +$156K ﹤0.01% 5279
2017
Q4 		$117K Buy
70
+69
+6,900% +$91.2K ﹤0.01% 5677
2017
Q3 		$2K Sell
1
-66
-99% -$77.5K ﹤0.01% 6859
2017
Q2 		$75K Buy
67
+45
+205% +$37.2K ﹤0.01% 5720
2017
Q1 		$12K Buy
22
+6
+38% +$3.68K ﹤0.01% 6486
2016
Q4 		$10K Sell
16
-9
-36% -$5.62K ﹤0.01% 6553
2016
Q3 		$18K Buy
25
+23
+1,150% +$17.6K ﹤0.01% 6169
2016
Q2 		$1K Buy
+2
New +$1.38K ﹤0.01% 6989
2015
Q1 		– Sell
-60
Closed -$43K – 7249
2014
Q4 		$43K Hold
60
– – ﹤0.01% 6422
2014
Q3 		$41K Sell
60
-278
-82% -$225K ﹤0.01% 6633
2014
Q2 		$285K Buy
+338
New +$336K ﹤0.01% 5206

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bank of America's CBIO Position: Q1 2026 in Review

Bank of America increased its Crescent Biopharma (CBIO) stake by 425% in Q1 2026, buying an estimated $272K and bringing the position to 29,277 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #4858.

Bank of America first reported a position in CBIO in Q2 2014 and has held it in 43 quarters since. The position peaked at $631K in Q2 2018. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Bank of America held 29,277 shares of Crescent Biopharma worth $538K as of Q1 2026.
  • Bank of America bought 23,704 Crescent Biopharma shares in Q1 2026, an estimated $272K.
  • Crescent Biopharma made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4858 holding.
  • Bank of America first reported a position in Crescent Biopharma in Q2 2014 and has held it in 43 quarters since.
  • Bank of America's Crescent Biopharma position peaked at $631K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.